February 14, 2018 / 6:17 AM / 7 days ago

BRIEF-Roche says FDA Grants Priority Review For Mabthera/ Rituxan For Pemphigus Vulgaris

Feb 14 (Reuters) - Roche Holding AG:

* ROCHE HOLDING AG - FDA GRANTS PRIORITY REVIEW FOR ROCHE’S MABTHERA/ RITUXAN (RITUXIMAB) FOR PEMPHIGUS VULGARIS Source text for Eikon: Further company coverage: (Reporting By Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below